Top-Rated StocksTop-RatedNASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis $18.91 -1.55 (-7.58%) Closing price 04:00 PM EasternExtended Trading$18.95 +0.04 (+0.24%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Summit Therapeutics Stock (NASDAQ:SMMT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Summit Therapeutics alerts:Sign Up Key Stats Today's Range$18.54▼$19.6450-Day Range$17.78▼$23.7652-Week Range$2.10▼$33.89Volume3.45 million shsAverage Volume3.44 million shsMarket Capitalization$13.95 billionP/E RatioN/ADividend YieldN/APrice Target$35.44Consensus RatingBuy Company OverviewSummit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Read More… Remove Ads Summit Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreSMMT MarketRank™: Summit Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 408th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingSummit Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSummit Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Summit Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.30) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -67.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -67.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 171.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Summit Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.59% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Summit Therapeutics has recently decreased by 1.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted24.59% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Summit Therapeutics has recently decreased by 1.90%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.64 News SentimentSummit Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Summit Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 15 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows8 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders88.30% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.61% of the stock of Summit Therapeutics is held by institutions.Read more about Summit Therapeutics' insider trading history. Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SMMT Stock News Headlines3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 MonthsApril 3 at 9:45 AM | fool.comS&P 500 Futures Fall in Premarket Trading; Axsome Therapeutics, First Horizon LagApril 1 at 10:32 AM | marketwatch.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 3, 2025 | Porter & Company (Ad)Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged TodayMarch 31 at 3:25 PM | fool.comWant $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.March 31 at 4:53 AM | fool.comCitigroup Upgrades Summit Therapeutics (BMV:SMMT)March 28, 2025 | nasdaq.comCitigroup Upgrades Summit Therapeutics (SMMT)March 27, 2025 | msn.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Buy" at CitigroupMarch 27, 2025 | americanbankingnews.comSee More Headlines SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed this year? Summit Therapeutics' stock was trading at $17.84 at the beginning of the year. Since then, SMMT stock has increased by 6.0% and is now trading at $18.91. View the best growth stocks for 2025 here. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings results on Monday, February, 24th. The company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). The firm had revenue of $0.20 million for the quarter. When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings2/24/2025Today4/03/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SMMT CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$35.44 High Stock Price Target$44.00 Low Stock Price Target$30.00 Potential Upside/Downside+87.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-85.42% Return on Assets-52.66% Debt Debt-to-Equity RatioN/A Current Ratio8.31 Quick Ratio8.31 Sales & Book Value Annual Sales$700,000.00 Price / Sales19,927.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book171.91Miscellaneous Outstanding Shares737,680,000Free Float86,281,000Market Cap$13.95 billion OptionableOptionable Beta-1.04 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:SMMT) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.